Skip to main content
Top
Published in: Pathology & Oncology Research 2/2012

01-04-2012 | Research

Periacinar Retraction Clefting in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular Involvement

Authors: Wagner José Fávaro, Amanda Cia Hetzl, Leonardo Oliveira Reis, Ubirajara Ferreira, Athanase Billis, Valéria Helena A. Cagnon

Published in: Pathology & Oncology Research | Issue 2/2012

Login to get access

Abstract

A space between neoplastic acini and prostatic stroma is not rare and studies have interpreted this as an artifact, considering the absence of endothelial cells indicating vascular invasion. Thus, the aims of this work were to characterize and correlate the occurrence and extent of retraction clefting with the reactivities of α and β dystroglycan (αDG, βDG), laminin, matrix metalloproteinase 2 (MMP-2), p63, insulin-like growth factor 1(IGF-1), vimentin, and fibroblast growth factor 2 (FGF-2). The study was based on nonneoplastic and neoplastic prostatic tissues obtained from necropsies and retropubic radical prostatectomies. The results showed that periacinar retraction clefting was significantly more frequent in prostatic carcinoma samples than in normal prostatic acini. Most of the neoplastic acini (72.0%) showed retraction clefting of more than 50% of circumference, which were significantly more frequent in Gleason score 7 and 6. Decreased collagen and reticular and elastic fibers were verified in the stroma around neoplastic acini. Weak and discontinuous αDG, βDG, and laminin immunoreactivities and intensified MMP-2, vimentin, IGF-1 and FGF-2 immunoreactivities were verified in the neoplastic acini; p63 immunoreactivity was negative in all carcinomas. Thus, these findings showed that the lack of epithelial basal cells, DGs, and laminin and increased MMP-2, IGF-1, and FGF-7 could be considered important pathways in periacinar retraction occurrence. This study demonstrated the origin of and the biological mechanisms responsible for periacinar retraction clefting in prostatic carcinoma.
Literature
1.
go back to reference Epstein JI (1995) Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 26:223–229PubMedCrossRef Epstein JI (1995) Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Hum Pathol 26:223–229PubMedCrossRef
2.
go back to reference Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PGO, Amin MB (2002) Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. Arch Pathol Lab Med 126:554–561PubMed Varma M, Lee MW, Tamboli P, Zarbo RJ, Jimenez RE, Salles PGO, Amin MB (2002) Morphologic criteria for the diagnosis of prostatic adenocarcinoma in needle biopsy specimens. Arch Pathol Lab Med 126:554–561PubMed
3.
go back to reference Krušlin B, Tomas D, Rogatsch H, Novosel I, Cupić H, Belicza M, Kraus O, Mikuz G (2003) Periacinar retraction clefting in the prostatic needle core biopsies: an important diagnostic criterion or a simple artifact? Virchows Arch 443:524–527PubMedCrossRef Krušlin B, Tomas D, Rogatsch H, Novosel I, Cupić H, Belicza M, Kraus O, Mikuz G (2003) Periacinar retraction clefting in the prostatic needle core biopsies: an important diagnostic criterion or a simple artifact? Virchows Arch 443:524–527PubMedCrossRef
4.
go back to reference Baisden BL, Kahane H, Epstein JI (1999) Perineural invasion, mucinous fibroplasia and glomerulations: diagnostic features on prostate needle biopsy. Am J Surg Pathol 23:918–924PubMedCrossRef Baisden BL, Kahane H, Epstein JI (1999) Perineural invasion, mucinous fibroplasia and glomerulations: diagnostic features on prostate needle biopsy. Am J Surg Pathol 23:918–924PubMedCrossRef
5.
go back to reference Durham JR, Lee MW, Amin MB, Shulz DS, Stetler-Stevenson WG (1994) Clefting in adenocarcinoma of the prostate gland. Am J Clin Pathol 102:536 Durham JR, Lee MW, Amin MB, Shulz DS, Stetler-Stevenson WG (1994) Clefting in adenocarcinoma of the prostate gland. Am J Clin Pathol 102:536
6.
go back to reference Krušlin B, Novosel I, Reljić A, Čupić H, Spajić B, Belicza M (2002) Periacinar cleft-like spaces in prostatic needle core biopsies. Acta Clin Croat 41:175 Krušlin B, Novosel I, Reljić A, Čupić H, Spajić B, Belicza M (2002) Periacinar cleft-like spaces in prostatic needle core biopsies. Acta Clin Croat 41:175
7.
go back to reference Krušlin B, Tomas D, Cviko A (2006) Periacinar retraction clefting and p63 immunostaining in prostatic intraepithelial neoplasia and prostatic carcinoma. Pathol Oncol Res 12:205–209PubMedCrossRef Krušlin B, Tomas D, Cviko A (2006) Periacinar retraction clefting and p63 immunostaining in prostatic intraepithelial neoplasia and prostatic carcinoma. Pathol Oncol Res 12:205–209PubMedCrossRef
8.
go back to reference Dean JP, Nelson PS (2008) Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 98:245–249PubMedCrossRef Dean JP, Nelson PS (2008) Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 98:245–249PubMedCrossRef
9.
go back to reference Cornell RJ, Rowley D, Wheller T (2003) Neuroepithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma. Urology 61:870–875PubMedCrossRef Cornell RJ, Rowley D, Wheller T (2003) Neuroepithelial interactions in prostate cancer are enhanced in the presence of prostatic stroma. Urology 61:870–875PubMedCrossRef
10.
go back to reference Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP, Cittadini A (2003) Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 162:849–860PubMedCrossRef Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP, Cittadini A (2003) Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 162:849–860PubMedCrossRef
11.
go back to reference Brennan PA, Jing J, Ethunandan M, Gorecki D (2004) Dystroglycan complex in cancer. Eur J Surg Oncol 30:589–592PubMedCrossRef Brennan PA, Jing J, Ethunandan M, Gorecki D (2004) Dystroglycan complex in cancer. Eur J Surg Oncol 30:589–592PubMedCrossRef
12.
go back to reference Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Faraglia B, Boninsegna A, Maiorana A, Cittadini A (2007) Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 213:528–539PubMedCrossRef Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Faraglia B, Boninsegna A, Maiorana A, Cittadini A (2007) Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 213:528–539PubMedCrossRef
13.
go back to reference Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225–233PubMedCrossRef Djavan B, Waldert M, Seitz C, Marberger M (2001) Insulin-like growth factors and prostate cancer. World J Urol 19:225–233PubMedCrossRef
14.
go back to reference Reynolds AR, Kyprianou N (2006) Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2:S144–S152CrossRef Reynolds AR, Kyprianou N (2006) Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2:S144–S152CrossRef
15.
go back to reference Mostofi FK, Price EBJr (1973) Tumors of the male genital system, atlas of tumor pathology, second series, fascicle 8. Armed Forces Institute of Pathology, Washington, pp 202–217 Mostofi FK, Price EBJr (1973) Tumors of the male genital system, atlas of tumor pathology, second series, fascicle 8. Armed Forces Institute of Pathology, Washington, pp 202–217
16.
go back to reference Tomas D, Krušlin B (2004) The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 61:324–331PubMedCrossRef Tomas D, Krušlin B (2004) The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 61:324–331PubMedCrossRef
17.
go back to reference Halpert B, Sheehan EA, Schmalhorst WR, Scott RJ (1963) Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 16:736–742CrossRef Halpert B, Sheehan EA, Schmalhorst WR, Scott RJ (1963) Carcinoma of the prostate: a survey of 5000 autopsies. Cancer 16:736–742CrossRef
18.
go back to reference Krušlin B, Tomas D, Rogatsch H, Reljić A, Vucić M, Balicević D, Belicza M, Mikuz G (2005) Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma. Int J Surg Pathol 13:67–72PubMedCrossRef Krušlin B, Tomas D, Rogatsch H, Reljić A, Vucić M, Balicević D, Belicza M, Mikuz G (2005) Correlation of periacinar retraction clefting in needle core biopsies and corresponding prostatectomy specimens of patients with prostatic adenocarcinoma. Int J Surg Pathol 13:67–72PubMedCrossRef
19.
go back to reference Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (1998) Atlas of tumor pathology. AFIP, Washington, pp 124–171 Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (1998) Atlas of tumor pathology. AFIP, Washington, pp 124–171
20.
go back to reference Tomas D, Ulamec M, Hudolin T (2006) Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Prostate Cancer Prostatic Dis 9:414–419PubMedCrossRef Tomas D, Ulamec M, Hudolin T (2006) Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma. Prostate Cancer Prostatic Dis 9:414–419PubMedCrossRef
21.
go back to reference Tomas D, Spajić B, Milošević M, Demirović A, Marušić Z, Krušlin B (2011) Extensive retraction artefact predicts biochemical recurrence-free survival in prostatic carcinoma. Histopathology 58:447–454PubMedCrossRef Tomas D, Spajić B, Milošević M, Demirović A, Marušić Z, Krušlin B (2011) Extensive retraction artefact predicts biochemical recurrence-free survival in prostatic carcinoma. Histopathology 58:447–454PubMedCrossRef
22.
go back to reference Djakiew D (2000) Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42:150–160PubMedCrossRef Djakiew D (2000) Deregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42:150–160PubMedCrossRef
23.
go back to reference Stangelberger A, Schally AV, Jl V, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M (2005) Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HERfam ily in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 64:303–315PubMedCrossRef Stangelberger A, Schally AV, Jl V, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M (2005) Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HERfam ily in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate 64:303–315PubMedCrossRef
24.
go back to reference Garrison JB, Kyprianou N (2004) Novel targeting of apoptosis pathways for prostate cancer therapy. Cur Cancer Drug Targets 4:85–95CrossRef Garrison JB, Kyprianou N (2004) Novel targeting of apoptosis pathways for prostate cancer therapy. Cur Cancer Drug Targets 4:85–95CrossRef
25.
go back to reference Stattin P, Rinaldi S, Biessy C, Stenman Uh, Hallmans G, Kaaks R (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22:3104–3112PubMedCrossRef Stattin P, Rinaldi S, Biessy C, Stenman Uh, Hallmans G, Kaaks R (2004) High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22:3104–3112PubMedCrossRef
26.
go back to reference Kwabi-Addo B, Ozen M, Ittmann M (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11:709–724PubMedCrossRef Kwabi-Addo B, Ozen M, Ittmann M (2004) The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 11:709–724PubMedCrossRef
27.
go back to reference Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, Czubayko F (2001) An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 92:510–517PubMedCrossRef Aigner A, Butscheid M, Kunkel P, Krause E, Lamszus K, Wellstein A, Czubayko F (2001) An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer 92:510–517PubMedCrossRef
28.
go back to reference Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063–1071PubMed Giri D, Ropiquet F, Ittmann M (1999) Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5:1063–1071PubMed
29.
go back to reference Lynch C, Matrisian L (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573PubMedCrossRef Lynch C, Matrisian L (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573PubMedCrossRef
30.
go back to reference Ross J, Kaur P, Sheehan C, Hugh B, Fisher H, Kauffman R, Kallakury B (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198–205PubMedCrossRef Ross J, Kaur P, Sheehan C, Hugh B, Fisher H, Kauffman R, Kallakury B (2003) Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198–205PubMedCrossRef
31.
go back to reference Martin MD, Matrisian LM (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26:717–724PubMedCrossRef Martin MD, Matrisian LM (2007) The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 26:717–724PubMedCrossRef
32.
go back to reference Mack CF, Knox JD, Powell WC, Nagle RB, Bowden GT (1993) Functional-role of the metalloproteinase matrilysin in human prostate-cancer. Int J Radiat Oncol Biol Phys 27:217 Mack CF, Knox JD, Powell WC, Nagle RB, Bowden GT (1993) Functional-role of the metalloproteinase matrilysin in human prostate-cancer. Int J Radiat Oncol Biol Phys 27:217
33.
go back to reference Gianelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson W, Quaranta V (1997) Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277:225–228CrossRef Gianelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson W, Quaranta V (1997) Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277:225–228CrossRef
34.
go back to reference Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, Shimizu T, Matsumura K (2001) Processing of β-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 10:1563–1569PubMedCrossRef Yamada H, Saito F, Fukuta-Ohi H, Zhong D, Hase A, Arai K, Okuyama A, Maekawa R, Shimizu T, Matsumura K (2001) Processing of β-dystroglycan by matrix metalloproteinase disrupts the link between the extracellular matrix and cell membrane via the dystroglycan complex. Hum Mol Genet 10:1563–1569PubMedCrossRef
35.
go back to reference Henry MD, Cohen MB, Campbell KP (2001) Reduced expression of dystroglican in breast and prostate cancer. Hum Pathol 32:791–795PubMedCrossRef Henry MD, Cohen MB, Campbell KP (2001) Reduced expression of dystroglican in breast and prostate cancer. Hum Pathol 32:791–795PubMedCrossRef
36.
go back to reference Gilles C, Thompson EW (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 2:83–96CrossRef Gilles C, Thompson EW (1996) The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 2:83–96CrossRef
37.
go back to reference Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454PubMedCrossRef
38.
go back to reference Zhao Y, Yan Q, Long X, Chen X, Wang Y (2008) Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 26:571–577PubMedCrossRef Zhao Y, Yan Q, Long X, Chen X, Wang Y (2008) Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 26:571–577PubMedCrossRef
Metadata
Title
Periacinar Retraction Clefting in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular Involvement
Authors
Wagner José Fávaro
Amanda Cia Hetzl
Leonardo Oliveira Reis
Ubirajara Ferreira
Athanase Billis
Valéria Helena A. Cagnon
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9440-5

Other articles of this Issue 2/2012

Pathology & Oncology Research 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine